Alpha-Conotoxin EI is the only peptide known to bind with much higher affinity to the agonist site at the alphadelta subunit interface of the electric organ acetylcholine receptor (AChR) than to the other agonist site of the alphagamma interface. The objective of this research proj4ect is to determine which amino acids on the delta subunit and on EI interact to produce this unique selectivity. The three specific aims to achieve this are 1) to identify the EI high-affinity determinant residues on the delta chain by making deltagamma and gammadelta chimeras and delta and gamma point mutants and measuring the loss or gain of EI high affinity when these are co-expressed in cells along with the wild-type ACHR subunits, 2) to identify the high-affinity determinant residues on EI by making EI analogues which substitute an alanine in which non-cysteine position and observing how this affects peptide affinity for wild-type ACHR and 3) to test if the high-affinity determinant residue pairs identified in Aims 1 and 2 interact with each other by using double- mutant cycle analysis. Peptide affinity will be estimated from its competition with the AChR-specific radioligand, 125I-alpha- bungarotoxin. These studies will give a clearer understanding of the structure of this receptor and how alpha-conotoxins bind to it. This should lead to a better understanding of homologous human receptors, such as the muscle and neuronal AChRs, and their involvement in various neurological disease processes. Alpha-Conotoxins like EI show clinical promise as potential neuromuscular and neuronal blocking agents and as site-specific probes to aid in the development of such agents.

Project Start
2002-02-15
Project End
2005-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
8
Fiscal Year
2002
Total Cost
$145,314
Indirect Cost
Name
Universidad Central Del Caribe
Department
Type
DUNS #
City
Bayamon
State
PR
Country
United States
Zip Code
00960
Ferchmin, P A; Pérez, Dinely; Castro Alvarez, William et al. (2013) ?-Aminobutyric acid type A receptor inhibition triggers a nicotinic neuroprotective mechanism. J Neurosci Res 91:416-25
Jiménez-Rivera, Carlos A; Figueroa, Johnny; Vázquez-Torres, Rafael et al. (2012) Presynaptic inhibition of glutamate transmission by ?2 receptors in the VTA. Eur J Neurosci 35:1406-15
Arencibia-Albite, Francisco; Vázquez, Rafael; Velásquez-Martinez, María C et al. (2012) Cocaine sensitization inhibits the hyperpolarization-activated cation current Ih and reduces cell size in dopamine neurons of the ventral tegmental area. J Neurophysiol 107:2271-82
Martins, Antonio H; Alves, Janaina M; Perez, Dinely et al. (2012) Kinin-B2 receptor mediated neuroprotection after NMDA excitotoxicity is reversed in the presence of kinin-B1 receptor agonists. PLoS One 7:e30755
Schwarz, David; Bloom, Damaris; Castro, Rocío et al. (2011) Parthenolide Blocks Cocaine's Effect on Spontaneous Firing Activity of Dopaminergic Neurons in the Ventral Tegmental Area. Curr Neuropharmacol 9:17-20
Martínez-Montemayor, Michelle M; Otero-Franqui, Elisa; Martinez, Joel et al. (2010) Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. Clin Exp Metastasis 27:465-80
Inyushin, Mikhail; Kucheryaykh, Yuri; Kucheryavykh, Lilia et al. (2010) Membrane potential and pH-dependent accumulation of decynium-22 (1,1'-diethyl-2,2'-cyanine iodide) flourencence through OCT transporters in astrocytes. Bol Asoc Med P R 102:5-12
Boukli, Nawal M; Saiyed, Zainulabedin M; Ricaurte, Martha et al. (2010) Implications of ER stress, the unfolded protein response, and pro- and anti-apoptotic protein fingerprints in human monocyte-derived dendritic cells treated with alcohol. Alcohol Clin Exp Res 34:2081-8
Inyushin, Mikhail; Kucheryavykh, Lilia Y; Kucheryavykh, Yuriy V et al. (2010) Potassium channel activity and glutamate uptake are impaired in astrocytes of seizure-susceptible DBA/2 mice. Epilepsia 51:1707-13
Acevedo-Torres, Karina; Berríos, Lexsy; Rosario, Nydia et al. (2009) Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst) 8:126-36

Showing the most recent 10 out of 51 publications